[1] Hautmann AH, Hautmann MG, Kölbl O, et al.  Tumor-induced osteomalacia: an up-to-date review[J]. Curr Rheumatol Rep, 2015, 17(6): 512-.   doi: 10.1007/s11926-015-0512-5
[2]

Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia[J/OL]. Bone Rep, 2017, 7: 90−97[2020-05-14]. https://www.sciencedirect.com/science/article/pii/S235218721730027X?via%3Dihub. DOI: 10.1016/j.bonr.2017.09.002.
[3] 徐加利, 余卫, 王华, 等.  肿瘤源性骨软化症责任肿瘤的CT和MRI表现[J]. 临床放射学杂志, 2017, 36(8): 1165-1169.   doi: 10.13437/j.cnki.jcr.2017.08.030
Xu JL, Yu W, Wang H, et al.  CT and MRI manifestations of TIO tumors[J]. J Clin Radiol, 2017, 36(8): 1165-1169.   doi: 10.13437/j.cnki.jcr.2017.08.030
[4] Rayamajhi SJ, Yeh R, Wong T, et al.  Tumor-induced osteomalacia—current imaging modalities and a systematic approach for tumor localization[J]. Clin Imaging, 2019, 56: 114-123.   doi: 10.1016/j.clinimag.2019.04.007
[5] Folpe AL.  Phosphaturic mesenchymal tumors: a review and update[J]. Semin Diagn Pathol, 2019, 36(4): 260-268.   doi: 10.1053/j.semdp.2019.07.002
[6]

Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classification of tumours of soft tissue and bone[M]. 4th ed. Lyon: IARC Press, 2013: 211−212.
[7] Chong WH, Molinolo AA, Chen CC, et al.  Tumor-induced osteomalacia[J]. Endocr Relat Cancer, 2011, 18(3): R53-R77.   doi: 10.1530/ERC-11-0006
[8] Kumar R, Folpe AL, Mullan BP.  Tumor-induced osteomalacia[J]. Transl Endocrinol Metab, 2015, 7(3): 1871-.   doi: 10.1210/TEAM.9781879225855.ch6
[9] 吴博, 夏维波.  肿瘤性骨软化症病理特点及致瘤基因[J]. 中华骨质疏松和骨矿盐疾病杂志, 2016, 9(2): 186-192.   doi: 10.3969/j.issn.1674-2591.2016.02.014
Wu B, Xia WB.  Pathologic characters and oncogene of tumor induced osteomalacia[J]. Chin J Osteoporos Bone Miner Res, 2016, 9(2): 186-192.   doi: 10.3969/j.issn.1674-2591.2016.02.014
[10] Xiao X, Sun XF, Ni PW, et al.  Phosphaturic mesenchymal tumor and related wound problem[J]. Medicine (Baltimore), 2018, 97(40): e12507-.   doi: 10.1097/MD.0000000000012507
[11] 邵怡, 王安平, 王先令, 等.  肿瘤相关性低磷骨软化症的诊疗进展[J]. 国际内分泌代谢杂志, 2017, 37(2): 112-115.   doi: 10.3760/cma.j.issn.1673-4157.2017.02.011
Shao Y, Wang AP, Wang XL, et al.  Diagnosis and treatment of tumor induced osteomalacia[J]. Int J Endocrinol Metab, 2017, 37(2): 112-115.   doi: 10.3760/cma.j.issn.1673-4157.2017.02.011
[12] Broski SM, Folpe AL, Wenger DE.  Imaging features of phosphaturic mesenchymal tumors[J]. Skeletal Radiol, 2019, 48(1): 119-127.   doi: 10.1007/s00256-018-3014-5
[13] Reubi JC, Waser B, Laissue JA, et al.  Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification[J]. Cancer Res, 1996, 56(8): 1922-1931.
[14] Yang M, Doshi KB, Roarke MC, et al.  Molecular imaging in diagnosis of tumor-induced osteomalacia[J]. Curr Probl Diagn Radiol, 2019, 48(4): 379-386.   doi: 10.1067/j.cpradiol.2018.06.005
[15] Jing HL, Li F, Zhuang HM, et al.  Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan[J]. Eur J Radiol, 2013, 82(11): 2028-2034.   doi: 10.1016/j.ejrad.2013.04.006
[16] Sood A, Agarwal K, Shukla J, et al.  Bone scintigraphic patterns in patients of tumor induced osteomalacia[J]. Indian J Nucl Med, 2013, 28(3): 173-175.   doi: 10.4103/0972-3919.119541